Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTLBiotechnology
+$0.03 today
- Market cap
- $133.64M
- Beta
- 1.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.77
Volume 1.45M
Average 2.00M
Returns on capital
Zentalis Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-63.4%
avg -59.4%
ROIC
-59.6%
avg -54.1%
ROA
-47.4%
avg -43.7%
Analysis
ROA is currently the strongest return metric at -47.4% versus its period average of -43.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Julie Eastland | Chief Executive Officer, President & Director | USD 1.14M | 62 | — | — |
Ingmar Bruns | Chief Medical Officer | USD 825.95K | 51 | 43.06K | 0.06% |
James Bucher | Chief Legal Officer & Corporate Secretary | USD 556.68K | 60 | — | — |
Vincent Vultaggio | SVP of Finance & Principal Accounting Officer | — | 42 | 146.51K | 0.21% |
Rajesh Israni | Executive VP of Regulatory Affairs & Medical Writing | — | — | — | — |
Robert J. DiVasto | Chief Technical Officer | — | 70 | — | — |
Henry Gu | Senior Vice President & Head of Intellectual Property | — | — | — | — |
Sarah Kelly | Senior Vice President of Commercial Strategy | — | — | — | — |
Haibo Wang | Chief Business Officer | — | — | — | — |
Wendy Chang | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$22.92M
Sells
10
$10.11M
Net Transaction Value
+$12.81M
Net buying
Most Active
Vultaggio Vincent
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 14, 26Aug 14, 2026 | WALTERS GROUP Direct | Buy | $15.2M$15,172,500.00 |
| Feb 10, 26Feb 10, 2026 | Vultaggio Vincent Direct | Sell | $16.7K$16,699.34 |
| Feb 9, 26Feb 9, 2026 | Vultaggio Vincent Direct | Sell | $8.1K$8,085.61 |
| Feb 9, 26Feb 9, 2026 | Bruns Ingmar Direct | Sell | $801.6$801.62 |
| Feb 9, 26Feb 9, 2026 | EASTLAND JULIA MARIE Direct | Sell | $2.1K$2,127.29 |
| Feb 6, 26Feb 6, 2026 | Bruns Ingmar Direct | Sell | $7.2K$7,196.77 |
| Feb 6, 26Feb 6, 2026 | EASTLAND JULIA MARIE Direct | Sell | $19.1K$19,112.02 |
| Feb 6, 26Feb 6, 2026 | Vultaggio Vincent Direct | Sell | $72.8K$72,771.94 |
| Feb 3, 26Feb 3, 2026 | Vultaggio Vincent Direct | Sell | $1.4K$1,398.34 |
| Feb 2, 26Feb 2, 2026 | Vultaggio Vincent Direct | Sell | $6.5K$6,477.00 |
1–10 of 12
Summary
Insiders reported 2 buys worth $22.92M and 10 sells worth $10.11M over the last 12 months. That adds up to net buying of $12.81M. Vultaggio Vincent was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Zentalis Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ZNTL's management, answered from reported figures.
Who manages ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) lists 10 active executives. The top listed executive is Vincent Vultaggio, SVP of Finance & Principal Accounting Officer.
Are ZNTL insiders buying or selling?
Recent insider activity shows net buying of $230.54M.
Continue the stock analysis
Jump to another research area for this company.